The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
- 
      
  
Target Advancement Program, 2016Targeting the LRRK2-PAK6 Pathway in Parkinson's DiseaseStudy Rationale: 
 LRRK2 is one of the most attractive therapeutic targets in Parkinson's disease (PD); however, chronic doses of LRRK2 inhibitors result in side effects in pre-clinical models. We...
- 
      
  
Improved Biomarkers and Clinical Outcome Measures, 2016Study of Drug Binding Sites in Alpha-synuclein FibrilsObjective/Rationale: 
 This research aims to improve the potential to treat Parkinson's disease (PD) by using active molecules. Various small molecules that produce desired effects have been shown to...
- 
      
  
Biomarkers Across Neurodegenerative Diseases, 2016Cross-disease Brain Image ModelingStudy Rationale: Individuals with Alzheimer’s and Parkinson’s diseases share typical brain image patterns. The research field has long awaited an intelligent system that could interpret patterns... 
- 
      
  
Target Advancement Program, 2016Validation of Cyclin-G Associated kinase (GAK) as a Target for Parkinson's DiseaseStudy Rationale: The project will investigate Cyclin-G associated kinase (GAK), a candidate risk gene for Parkinson’s disease (PD), based on genome-wide association studies (GWAS)... 
- 
      
  
Target Advancement Program, 2016Insights into LRRK2 Kinase InhibitorsStudy Rationale: 
 Mutations in LRRK2 cause an inherited form of Parkinson's disease (PD), and variations in LRRK2 can increase disease risk, indicating that the protein is key in the entire PD disease...
- 
      
  
Therapeutic Pipeline Program, 2016Novel LRRK2 Antisense Oligonucleotides as a Therapy for Parkinson's DiseaseStudy Rationale: 
 LRRK2 gain-of-function gene mutations (R1441C and G2019S) are one of the most prevalent mutations contributing to inherited Parkinson's disease (PD). Altered LRRK2 function has also...
 
  Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.